All In Biotech

Drug Trial Radar · NCT01870024

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients

Last checked: Nov 19, 2026Latest source record: Oct 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 434 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

434

Actual

Start

Jun 26, 2013

Primary completion

Feb 23, 2018

Study completion Feb 23, 2018

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to know on one hand if lorazepam is more (effective) than clonazepam and on the other hand if lorazepam is also effective as the association clonazepam + fosphenytoin in out-of-hospital treatment of the generalized convulsive status epilepticus in adult patients.

Conditions

  • Status Epilepticus
  • Epilepsy

Interventions

  • ClonazepamDrug

    clonazepam 0,015 mg/kg

  • FosphenytoinDrug

    fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

  • PlaceboDrug

    placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

  • LorazepamDrug

    lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patient with a cessation of seizures and absence of recurrenceTime frame: between 20 and 60 minutes after the beginning of the treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.